• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.

作者信息

Morabito Fortunato, Tripepi Giovanni, Del Poeta Giovanni, Mauro Francesca Romana, Reda Gianluigi, Sportoletti Paolo, Laurenti Luca, Coscia Marta, Herishanu Yair, Varettoni Marzia, Murru Roberta, Chiarenza Annalisa, Visentin Andrea, Condoluci Adalgisa, Moia Riccardo, Pietrasanta Daniela, Loseto Giacomo, Consoli Ugo, Scortechini Ilaria, Rossi Francesca Maria, Zucchetto Antonella, Vigna Ernesto, Martino Enrica Antonia, Mendicino Francesco, Botta Cirino, Caracciolo Daniele, Cassin Ramona, D'Arrigo Graziella, Galimberti Sara, Rago Angela, Angeletti Ilaria, Biagi Annalisa, Del Giudice Ilaria, Bomben Riccardo, Neri Antonino, Fronza Gilberto, Cutrona Giovanna, Rossi Davide, Di Raimondo Francesco, Cuneo Antonio, Gaidano Gianluca, Polliack Aaron, Trentin Livio, Foà Robin, Ferrarini Manlio, Gattei Valter, Gentile Massimo

机构信息

Department of Onco-Hematology, Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.

Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.

出版信息

Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

DOI:10.1002/ajh.26127
PMID:33580969
Abstract
摘要

相似文献

1
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.4因素评分评估：对586例接受依鲁替尼治疗的慢性淋巴细胞白血病（CLL）患者的回顾性分析。一项校园CLL研究。
Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
3
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
4
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
5
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.伊布替尼治疗的慢性淋巴细胞白血病（CLL）患者的心房颤动：风险预测、管理和临床结局。
Ann Hematol. 2021 Jan;100(1):143-155. doi: 10.1007/s00277-020-04094-3. Epub 2020 Jun 1.
6
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.伊布替尼治疗的 CLL 患者中核型复杂性和演变对生存的影响。
Blood. 2021 Dec 9;138(23):2372-2382. doi: 10.1182/blood.2020010536.
7
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
8
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.205 例慢性淋巴细胞白血病患者接受伊布替尼治疗的真实世界结果。
Eur J Haematol. 2020 Nov;105(5):646-654. doi: 10.1111/ejh.13499. Epub 2020 Aug 26.
9
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.新兴布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病：伊布替尼更进一步。
Expert Opin Emerg Drugs. 2020 Mar;25(1):25-35. doi: 10.1080/14728214.2020.1724282. Epub 2020 Feb 6.
10
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.

引用本文的文献

1
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.慢性淋巴细胞白血病：新药时代的预后因素
Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732.
2
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.CD49d表达被纳入一个经过修订的四因素模型，该模型可预测接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后：一项多中心真实世界研究。
Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul.
3
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
伊布替尼耐药慢性淋巴细胞白血病中克隆内增殖亚群的早期再现。
Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24.
4
Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.真实世界中 CLL 的诊断和治疗方法：来自托斯卡纳专家小组的 2022 年更新。
Clin Exp Med. 2023 Dec;23(8):4251-4264. doi: 10.1007/s10238-023-01244-5. Epub 2023 Nov 18.
5
Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?慢性淋巴细胞白血病中的突变与临床结局：仍需要一个阈值吗？
Hemasphere. 2023 Apr 4;7(4):e855. doi: 10.1097/HS9.0000000000000855. eCollection 2023 Apr.
6
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?观点：在化疗免疫治疗时代，如何定义高危慢性淋巴细胞白血病？
Front Oncol. 2023 Feb 9;13:1106579. doi: 10.3389/fonc.2023.1106579. eCollection 2023.
7
New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases".领域新成员：C反应蛋白与白蛋白比值作为慢性淋巴细胞白血病的新预后标志物：对《C反应蛋白与白蛋白比值是新诊断慢性淋巴细胞白血病的独立不良预后因素：322例临床分析》的评论
Transl Oncol. 2021 Aug;14(8):101098. doi: 10.1016/j.tranon.2021.101098.